{"id":8933,"date":"2024-10-01T16:07:20","date_gmt":"2024-10-01T20:07:20","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=8933"},"modified":"2024-10-01T16:07:20","modified_gmt":"2024-10-01T20:07:20","slug":"astrazeneca-expands-ai-powered-immuno-oncology-research-partnership-with-immunai","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/astrazeneca-expands-ai-powered-immuno-oncology-research-partnership-with-immunai\/","title":{"rendered":"AstraZeneca Expands AI-Powered Immuno-Oncology Research Partnership with Immunai"},"content":{"rendered":"<p>Immunai, a biotechnology company based in New York, has partnered with AstraZeneca in a multiyear endeavor to try and change the cancer immunotherapy trials through AI. This partnership will utilize Immunai\u2019s immune-cell atlas to optimize outcomes of clinical trials, decisions, and cancer treatment.<br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\nThe two have collaborated in research on IBD, as well as volrustomig, an antibody AstraZeneca is currently running trials on lung, cervical, head and neck cancers. Immunai\u2019s leading-edge technology applied for mapping the immune system and can thus regulate a single cell level to identify drug targets.<br \/>\nImmunai has been started by former researchers and professors from MIT, Harvard and Stanford universities and offers an AI-technology called the Immunodynamics Engine (IDE), in addition to the AMICA immune cell atlas. These tools are developed to gain certain knowledge about the role of immune cells and their relationship with diseases. Immunai was initially known for its work in the oncology field, especially immunotherapy but is working in autoimmune, CV, and neurological diseases now.<br \/>\nThe partnership follows on the back of Immunai\u2019s Series B funding that was held in 2021, with $215M raised and a Series A of $60M held earlier in the year. Such funds have complemented the growth of the company\u2019s research as well as technologist offerings, affirming the company\u2019s position as an Artificial Intelligence led drug discovery company.<br \/>\nWhen the new division of the partnership has been completed, Immunai will receive $18M from AstraZeneca for its AI platform. This collaboration is set to accelerate clinical trials of new cancer treatments by helping sort out which patients are most likely to benefit from a particular therapy, which dose is most effective, and what biomarkers exist for each drug.<br \/>\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script> <ins class=\"adsbygoogle\" style=\"display: block; text-align: center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins> <script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br \/>\nInsights from Immunai could help to rationalize clinical trial decisions and lend to the development of brand-new cancer treatments.<br \/>\nThe partnership is a part of the company\u2019s goal to incorporate AI in the creation of drugs. This comes after it closed a $247M deal with another artificial intelligence firm, Absci, to develop antibodies that target cancer. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Immunai, a biotechnology company based in New York, has partnered with AstraZeneca in a multiyear endeavor to try and change the cancer immunotherapy trials through AI. This partnership will utilize Immunai\u2019s immune-cell atlas to optimize outcomes of clinical trials, decisions, and cancer treatment. The two have collaborated in research on IBD, as well as volrustomig, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8934,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":{"0":"post-8933","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-commercial"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/8933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=8933"}],"version-history":[{"count":1,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/8933\/revisions"}],"predecessor-version":[{"id":8935,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/8933\/revisions\/8935"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/8934"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=8933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=8933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=8933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}